[Efficacy and safety of panitumumab for K-ras wild-type unresectable or recurrent colorectal cancer - a study focusing on first-line treatment].

Panitumumab was approved in June 2010 for use in the treatment of unresectable advanced/recurrent colorectal cancer. Here, we report outcomes and adverse events of panitumumab combination therapy or single-agent chemotherapy for K-ras wild-type unresectable or recurrent colorectal cancers. Our study focused on first-line treatments. The study involved 18 patients who started receiving panitumumab in October 2010. Nine patients received panitumumab as a first-line treatment; 4, as a second-line treatment; and 5, as a third-line or subsequent treatment. The overall response rate was 27.8%. Among the patients who received panitumumab as a first-line treatment, the response rate was 55.6%. Grade 1 and 2 skin disorders were common adverse events. Grade 2 interstitial pneumonia was observed in 1 patient(5.6%). Grade 3 or higher events comprised peripheral neuropathy in 1 patient(5.6%)and neutropenia in another patient(5.6%). The treatment was beneficial, and metastatic foci were resected in 3 patients. In this study, the only adverse events of Grade 3 or higher were 1 case each of peripheral neuropathy and neutropenia. Accordingly, adequate control seemed possible. The specific line of treatment that panitumumab should belong to remains controversial. However, active initiation as first-line treatment should be considered for cases in which resection of metastatic foci can be expected from tumor reductions due to panitumumab.
AuthorsShingo Mitomo, Takayuki Suto, Akira Umemura, Kaoru Ishida, Kiminori Kanno, Daiki Takeda, Tomonori Fujita, Koki Otsuka, Hiroyuki Nitta, Noriyuki Uesugi, Tamotsu Sugai, Go Wakabayashi
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 41 Issue 6 Pg. 731-5 (Jun 2014) ISSN: 0385-0684 [Print] Japan
PMID25129084 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • panitumumab
  • ras Proteins
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Colorectal Neoplasms (drug therapy, genetics, pathology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Proto-Oncogene Proteins (genetics)
  • Recurrence
  • ras Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: